Omeros Corporation (NASDAQ: OMER) is a Healthcare company (Biotechnology) with a market capitalization of $991M. The Maz Rating grades it against the other companies in its sector.
Omeros Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $13.69, Omeros Corporation trades at 10.5x trailing earnings and 31.4x sales, with an EV/EBITDA of 7.6. Over the last twelve months it generated about $32M of revenue and $94M of net income. It runs a gross margin of 93.6%, an operating margin of -109.1% and a net margin of 256.1%. It shows return on equity of -120.8%, return on invested capital of -21.7% and a free cash flow yield of -3.1%. On the balance sheet: a debt-to-equity ratio of -0.10 and a current ratio of 2.27. Over the past 52 weeks the share price ranged from $6.70 to $21.24, with a beta of 2.57.
Omeros Corporation does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 1 Strong Buy, 11 Buy, 5 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.